Medical & pharmaceutical industry news

See also: Articles in Hair Transplant Forum International

2024

Robertson J. New patient card to be introduced for finasteride. The Pharmacist (UK). May 2, 2024.

Safety update: psychiatric and sexual adverse effects with finasteride. Drug Ther Bull. 2024. doi:10.1136/dtb.2024.000036 • PubMed

Seven days in medicine: 1-7 May 2024 (see section: MHRA issues warning on finasteride side effects). BMJ. 2024 May 9. doi:10.1136/bmj.q1022

Stent J. Finasteride: MHRA warns of hair loss drug ‘psychiatric and sexual side effects’. Chemist+Druggist. May 1, 2024.

Wilkinson E. GPs alerted of side effects associated with prostate and hair loss drug. PulseToday (UK). May 3, 2024.

2023

Finasteride: potential risks of suicidal ideation and self-injury. Reactions Weekly. 2023;1942:5. doi:10.1007/s40278-023-32614-7

Haarwuchs mit Folgen: Das Post-Finasterid-Syndrom im Spiegel der Wissenschaft [Hair growth with consequences: post-finasteride syndrome in a scientific light]. Deutsche Apotheker Zeitung. 8 Mar 2023;10/23. German. Abstract in English via Post-Finasteride Syndrome Foundation.

2022

Besser verträgliche Alopezie-Therapie mit topischem Finasterid? [Better tolerated alopecia therapy with topical finasteride?]. DAZ.online. 2022 Feb 13. German.

2021

Ault A. New finasteride lawsuit brings renewed attention to psychiatric, ED adverse event reports. Medscape Medical News. September 23, 2021.

2020

Petrou I. Androgenetic alopecia risk IDed with genetic test. Dermatology Times. April 2020.

2019

Ramm-Fischer A. Gibt es ein Post-Finasterid-Syndrom? [Is there a post-finasteride syndrome?]. Kongressbericht: World Congress of Dermatology 2019. Schweizer Zeitschrift für Dermatologie. April 2019. German. View PDF

2018

Neuroaktive Steroide im Visier: ein Gespräch mit Prof. Dr. Michael Zitzmann zu den Hintergründen des Post-Finasterid-Syndroms [Neuroactive steroids in view: a conversation with Prof. Dr. Michael Zitzmann on the background of post-finasteride syndrome]. Deutsche Apotheker Zeitung. 19 Apr 2018;16:29. German.

2016

Post-finasteride syndrome. Prescriber Update (New Zealand). 2016 March;37(1):8-9. (Archived at archive.is)

Sohn JY. Generics to challenge GSK’s prostate, hair loss drug in Korea. Korea Herald. January 22, 2016.

2013

Collier R. Propecia lawsuits: the lasting effects of delayed drug warnings. CMAJ. 2013 Jul 9;185(10):E455-E456. doi:10.1503/cmaj.109-4488PubMed

Conaglen HM, Conaglen JV. Drug-induced sexual dysfunction in men and women. Aust Prescr. 2013 Apr 2;36:42-5. doi:10.18773/austprescr.2013.021

Moore T, et al. Finasteride (PROPECIA®) and persistent side effects. Inst Safe Medication Pract QuarterWatch. 2013 Jan 9:7–10.

2012

Case reports suggest a broader range of sexual adverse events in patients receiving finasteride [Propecia, Proscar] than previously reported. React Wkly. 2012;1398(2). doi:10.2165/00128415-201213980-00005

Does finasteride lead to permanent sexual side effects? The Dermatologist. 2012 Sep;20(9). Unavailable on website. Available on archive.org

2001

Direct to consumer advertising: finasteride for male pattern hair loss. Therapeutics Initiative. 2001 Apr 30:40.

1999

Blumenstyk G. Medical journal reviews policy on authors’ conflicts of interest. Chronicle of Higher Education. Oct 8, 1999; 46(7): A24.

1987

Merck prostate reducing agent MK-906 is in clinicals. The Pink Sheet. May 4, 1987.